FOXA2 and metabolic dysfunction-associated steatohepatitis: suggest that FOXA2 expression is reduced during hepatic steatosis, and FOXA2 regulates its target endogenous ALR level, which may lead to increased endoplasmic reticulum stress and lipid deposition, reduced fatty acid Β-oxidation, ultimately exacerbating the progression of NASH (73, 96).